Waldencast Receives Positive Nasdaq Listing Determination
- None.
- None.
Insights
The decision by the Nasdaq Hearings Panel to allow Waldencast continued listing on the Nasdaq, contingent on the filing of their interim financial statements, is a significant development. The ability to maintain a listing on a major exchange like Nasdaq provides a company with enhanced visibility and credibility among investors, which can be crucial for its stock liquidity and the ability to raise capital. The imposed deadline of April 1, 2024, for Waldencast to file the necessary financials suggests a tight timeline that the company must adhere to, which could indicate previous delays or issues in reporting. Investors should monitor the company's adherence to this deadline as it can serve as an indicator of the management's ability to address compliance issues and maintain operational transparency.
From a financial perspective, the conditional nature of Waldencast's continued listing highlights the importance of timely and accurate financial reporting. The interim financial statements for the six-month period ended June 30, 2023, will provide critical information about Waldencast's financial health and performance. Investors will be particularly interested in the company's revenue growth, profit margins, cash flows and balance sheet strength. Any deviation from the norm, either positive or negative, could significantly impact the stock's valuation. The requirement to file these statements could also suggest that there have been concerns about the company's financial disclosures, which may have led to the Nasdaq Hearings Panel's involvement. The outcome of this compliance will likely influence investor confidence and could lead to volatility in the company's stock price.
The legal implications of Waldencast's situation with Nasdaq are non-trivial. The Securities and Exchange Commission (SEC) requires public companies to file periodic financial statements to maintain transparency and protect investors. Failure to meet these requirements can result in penalties and, in severe cases, delisting. Waldencast's compliance with the Panel's decision is crucial to avoid such consequences. For stakeholders, this is an assurance that the company is taking necessary steps to rectify any issues and align with regulatory standards. Delisting can severely impact a company's stock due to reduced marketability and investor perception. This decision by the Panel, while positive, should be viewed with cautious optimism until Waldencast fulfills its obligations by the specified deadline.
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, today announced that by decision dated February 22, 2024, a Nasdaq Hearings Panel (the “Panel”) granted Waldencast’s request for continued listing on The Nasdaq Stock Market LLC (“Nasdaq”), subject to Waldencast filing the interim financial statements for the six-month period ended June 30, 2023 with the Securities and Exchange Commission by April 1, 2024, and Waldencast’s continued compliance with all other applicable criteria for continued listing on Nasdaq. Waldencast is diligently working to evidence compliance with the terms of the Panel’s decision as soon as practicable and in any event by no later than April 1, 2024.
About Waldencast
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the business combination with Obagi Skincare and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi- brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com/.
Obagi Skincare is an industry-leading, advanced skin care line rooted in research and skin biology, refined with a legacy of 30 years’ experience. First known as leaders in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi products are designed to diminish the appearance of premature aging, photodamage, skin discoloration, acne, and sun damage. More information about Obagi Skincare is available on the brand’s website, Facebook, Twitter and Instagram pages.
Founded in 2016, Milk Makeup quickly became a cult-favorite among the beauty community for its values of self-expression and inclusion, captured by its signature Live Your Look, its innovative formulas and clean ingredients. The brand creates vegan, cruelty-free, clean formulas from its Milk Makeup HQ in Downtown NYC. Currently, Milk Makeup offers over 300 products through its US website www.MilkMakeup.com, and its retail partners including Sephora in North America, Europe, the Middle East and Australia and Cult Beauty and Selfridges in the UK.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this release that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Waldencast’s ability to evidence compliance with the terms of the Panel’s decision as soon as practicable and in any event by no later than April 1, 2024; Waldencast’s ability to maintain its listing on Nasdaq; and any assumptions underlying any of the foregoing. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “should,” and “will” and variations of such words and similar expressions are intended to identify such forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of Waldencast, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements, including, among others: (i) the inability to recognize the anticipated benefits of the business combination with Obagi Skincare and Milk Makeup, (ii) failure by Waldencast to regain compliance with Nasdaq’s continued listing standards or failure by Waldencast to satisfy the terms of any extension granted, all of which may result in Waldencast’s securities being delisted from Nasdaq, (iii) the ability of Waldencast to file required financial results in a timely manner, (iv) Waldencast’s ability to successfully remediate the material weaknesses in Waldencast’s internal control over financial reporting, (v) the potential for delisting, legal proceedings or government investigations or enforcement actions, including those relating to the subject of the Audit Committee (the “Audit Committee”) of Waldencast’s Board of Directors’ review or inability to finalize financial results in a timely manner, (vi) Waldencast’s ability to obtain additional waivers from the Administrative Agent and the lenders under its credit facilities for any continuing or future defaults or events of default, (vii) volatility of Waldencast’s securities due to a variety of factors, including Waldencast’s inability to implement its business plans or meet or exceed its financial projections and changes, (viii) the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities, (ix) the ability of Waldencast to implement its strategic initiatives and continue to innovate Obagi Skincare’s and Milk Makeup’s existing products and anticipate and respond to market trends and changes in consumer preferences, (x) any shifts in the preferences of consumers as to where and how they shop, and (xi) social, political and economic conditions. These and other risks, assumptions and uncertainties are more fully described in the Risk Factors section of our 2022 20-F (File No. 01-40207), filed with the SEC on January 16, 2024, and in our other documents that we file or furnish with the SEC, which you are encouraged to read.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to rely on these forward-looking statements, which speak only as of the date they are made. Waldencast expressly disclaims any current intention, and assumes no duty, to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise.
Contacts
Investors
ICR
Allison Malkin/Lyn Walther
waldencastir@icrinc.com
Media
ICR
Brittney Fraser/Alecia Pulman
waldencast@icrinc.com
FAQ
What decision was made by the Nasdaq Hearings Panel regarding Waldencast plc (WALD)?
What is the deadline for Waldencast plc (WALD) to file interim financial statements?
What does Waldencast plc (WALD) need to do to maintain compliance with Nasdaq listing criteria?
